Ar II is optionally substituted phenyl;

A is  ;

B and E are a chemical bond;

a is 0-6;

b is 0-4;

c is 0;

d is 0;

g is 1-5;

R_1, R_2, R_3 and R_4 are, independently, hydrogen, halogen or optionally substituted alkyl;

Z is $R_{21}O_2C$-, $R_{21}OC$-, -CN, $R_{21}O_2SHNCO$-, $R_{21}O_2SHN$-, $(R_{21})_2NCO$- or $R_{21}O$-; and

R_{21} is independently hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, or optionally substituted aralkyl;

R_{15}, R_{16} are independently hydrogen, optionally substituted alkyl, optionally substituted aralkyl, carbonyl, or optionally substituted alkoxycarbonyl;

or a pharmaceutically acceptable salt thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

2. (Twice Amended) A compound according to claim 1 wherein Ar I is optionally substituted azaheteroaryl.

30. (Three Times Amended) A compound according to claim 1 wherein

Ar I is an optionally substituted quinolinyl, quinoxalinyl, quinazolinyl, isoquinolinyl, *N*-alkyl-quinolin-4-onyl, quinazolin-4-onyl, benzoxazolyl,

benzimidazolyl, benzothiazolyl, benzofuranyl, benzothiophenyl, oxazolyl, thiazolyl, oxadiazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiadiazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl group, wherein the substituent is a ring system substituent.

55. (Three Times Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound wherein the disorder is associated with a physiological detrimental blood level of insulin, glucose, free fatty acids, or triglycerides.

56. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is hyperglycemia.

59. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is hyperinsulinism.

61. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is insulin resistance.

~~62~~ 21. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is a cardiovascular condition.

~~64~~ 23. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is hyperlipidemia.

~~65~~ 24. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is hypertension.

~~66~~ 25. (Amended) A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, wherein the physiological disorder is an eating disorder.

97. (Twice Amended) A compound as claimed in claim 1, which is of formula



wherein



is optionally substituted heteroaryl;

a = 1;

b = 0;

R_1, R_2, R_3, R_4 are hydrogen

A is 

;

R_{15}, R_{16} are hydrogen;

c = 0;

d = 0;

g = 2, 3, 4 or 5;

B and E are a chemical bond;

Z is $R_{21}O_2C$-, $R_{21}OC$-, or $R_{21}O$-;

R_{21} is hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, or optionally substituted aralkyl;

09 Sub E4

R' is hydrogen, optionally substituted lower alkyl, halo, optionally substituted alkoxy, optionally substituted aryloxy or optionally substituted aralkyloxy; and
R" is optionally substituted lower alkyl, hydrogen, optionally substituted aralkyloxy, optionally substituted alkoxy, optionally substituted cycloalkylalkyloxy or halo, or
a pharmaceutically acceptable salt thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

102. (Amended) A compound according to claim 1, wherein the compound is

D10



Sub E7

D



D/o

Sub

E7

D

Sub E7



, or



D10

12

~~103.~~ (Amended) A compound according to claim 1, wherein the compound is

T1350



Please add new claim 104 as follows:

--104. A compound according to claim 1, wherein the compound is

D1 Sub E8



--